Psychedelic drugs-a new era in psychiatry?

Psychedelic substances such as mescaline, psilocybin and LSD have long histories of ritual and clinical use but were introduced to Western science only in the late 19th and early 20th centuries, with major developments after the discovery of LSD in 1943 and the isolation of psilocybin. Early mid-20th century research explored therapeutic applications across psychiatry and suggested safety advantages relative to contemporaneous psychotropics. However, widespread prohibition beginning in the 1960s (Schedule I classification) effectively halted clinical research for decades despite promising clinical signals. This paper reviews the recent renaissance of clinical and neuroscience research on classical psychedelics (notably psilocybin and LSD), MDMA, and related agents such as ketamine and ayahuasca. Nutt summarises historical context, neuropharmacology, key modern clinical trials (including both open-label and controlled studies), mechanistic neuroimaging findings, and practical challenges facing research and clinical translation. The review aims to appraise the current evidence base, highlight limitations, and outline the principal barriers and prospects for developing psychedelic-assisted treatments in psychiatry.

The extracted text does not present a formal Methods section or a documented systematic search strategy. The article functions as a narrative review and commentary that integrates historical material, preclinical pharmacology, human neuroimaging studies, and summaries of published clinical trials and pilot studies. The author draws on examples from controlled and open-label clinical work (including trials by Griffiths, Ross, Bogenschutz, Grob, Moreno and others), regulatory milestones (EMA and FDA permissions), and small pilot series to illustrate current evidence and ongoing trials. Because the paper is a narrative overview rather than a systematic review or meta-analysis, no explicit inclusion/exclusion criteria, database search dates, or formal quality appraisal method are reported in the extracted text. The review therefore summarises selected seminal and recent studies and discusses themes emerging across them rather than reporting pooled quantitative analyses.

Historical and epidemiological observations: Early research (1950s–1960s) produced many publications and clinical investigations of LSD and psilocybin; long-term follow-up of large numbers of LSD administrations reportedly did not show increased psychiatric morbidity. Six early trials investigated LSD for alcoholism and a modern meta-analysis of those data found LSD therapy at least as efficacious as available treatments. Ketamine and related agents: Clinical work beginning with intravenous ketamine showed rapid but transient antidepressant effects after a single IV dose, often lasting up to about 4 days. A commercially developed intranasal s-ketamine is noted and all forms require repeated dosing (typically twice weekly) to maintain effect. MDMA: Although not a classical psychedelic, MDMA has been used therapeutically (often in couple therapy) and has been studied for PTSD. The Mithoefers’ trials used sessions of MDMA (typical dosing described as 125 mg with a 62.5 mg top-up after about 2 hours) combined with exposure-based therapy and reported strong therapeutic effects. Regulatory agencies (FDA and EMA) have approved multicentre studies of MDMA for PTSD; the author also reports an open Bristol MDMA-for-alcoholism trial underway using a similar two-session regimen. Psilocybin: Modern clinical research includes several pilot and controlled studies across conditions. In addiction, Griffiths’ team gave 25 mg psilocybin three times in a structured smoking cessation programme (n = 15) and observed that 12 of 15 subjects were biologically confirmed smoking-free at 6 months. Bogenschutz and colleagues administered two psilocybin sessions to 10 alcohol-dependent patients and reported significant reductions in percentage of heavy drinking days. Depression and end-of-life anxiety: Nutt’s own open-label pilot in treatment-resistant depression gave a 10 mg test dose and a 25 mg therapeutic dose one week apart to 20 patients (mean prior failed medications ≈ 4.6, mean illness duration ≈ 17.7 years). Patients were withdrawn from serotonergic antidepressants and 5-HT2A-blocking antipsychotics beforehand. The primary outcome (QIDS-SR) showed highly significant improvements at all follow-up points up to 6 months, with maximal effect at about 5 weeks; however, interpretation is limited by the open-label design. Four controlled studies in life‑threatening cancer-related anxiety/depression were described: Grob et al. (n = 12) used moderate psilocybin versus niacin and found nonsignificant mood trends; Griffiths et al. (n = 51) used higher versus very low psilocybin doses in a double-blind crossover and showed superiority of the high dose at 5 weeks with associations between mystical-type experiences and enduring benefit; Ross et al. (n = 29) compared a single 0.3 mg/kg psilocybin dose with niacin and reported clinician- and participant-rated benefits lasting at least 7 weeks and sustained approximately 8 months; crossover to psilocybin produced immediate and sustained reductions in the prior placebo group. Ayahuasca and other psychedelics: Small open-label studies of ayahuasca in depressed patients (e.g. Osorio, n = 6; Sanches, n = 17) reported significant reductions on depression scales up to 2–3 weeks; a subsequent double-blind study is reported as positive. An LSD trial in Switzerland used low and high doses and, together with compassionate use in some jurisdictions, indicates continuing clinical interest in LSD. Safety, tolerability and practical findings: Across modern clinical programmes adverse events were uncommon when patients were carefully screened and sessions were medically supervised. The main safety concerns are precipitation or worsening of psychosis and possible induction of mania in bipolar disorder; therefore clinical protocols exclude people with personal or first-degree family histories of psychosis and often exclude bipolar disorder. Many patients do not find the psychedelic session enjoyable though they often judge it worthwhile afterwards. Preparedness and supervised integration are standard. Drug–drug interactions are clinically important: 5-HT2A‑blocking antipsychotics and SSRIs can reduce or block psychedelic effects, so withdrawal of such medications was commonly required and presents its own risks. Regulatory barriers are substantial: Schedule I status imposes procurement, time and cost burdens (the author reports an approximate cost of £1,500 per psilocybin administration and a two-year procurement period in his first study). Overall patient numbers in double-blind trials remain small (total under 200 across the field by inspection of Table I), limiting the strength of efficacy claims.

Nutt interprets the accumulated evidence as encouraging but preliminary: modern neuroscience and small clinical trials suggest that psychedelics and MDMA have therapeutic potential across several psychiatric indications, notably treatment-resistant depression, end-of-life anxiety/depression, PTSD (MDMA), and some substance-use disorders. He emphasises that the field is still in its infancy — few double-blind trials have been completed and total patient numbers are low — so claims about broad clinical usefulness must be cautious. Mechanistically, the author highlights 5-HT2A receptor agonism as the key pharmacological action for classical psychedelics, with robust evidence that 5-HT2A antagonists block psychedelic subjective effects. Neuroimaging work reported includes decreases in blood flow and BOLD activity in the default mode network and the subgenual cingulate cortex after psilocybin; these changes are discussed as potentially relevant to antidepressant effects because overactivity in these regions has been associated with depression. Nutt describes a model in which psychedelics disrupt maladaptive network dynamics (for example over-engagement of the DMN and rigid patterns of rumination), enabling a transiently ‘‘depressed-free’’ experience and possibly promoting synaptic or plastic changes that allow a longer-term reset of brain circuits. MDMA is characterised as acting differently — principally as a serotonin-releasing agent that dampens limbic activity (amygdala/hippocampus) and so facilitates therapeutic processing of traumatic memories. The authors acknowledge several important limitations and practical challenges. Prominent among these are small sample sizes, predominance of open-label designs in early work, difficulties in blinding due to the unmistakable subjective effects of psychedelics, and the intensive psychotherapy input required for preparation, supervision and integration. There are also safety constraints (risk of psychosis or mania), drug–drug interaction issues that necessitate careful medication withdrawal, and substantial legal and logistical barriers imposed by Schedule I classification that increase cost and slow research. The review notes unresolved questions such as the relative contribution of drug versus psychotherapeutic context, optimal dosing and number of sessions (including whether repeat dosing yields more durable remission), and the untested claims around microdosing. In terms of implications, the author observes that ongoing multicentre Phase II/III programmes (including EMA-approved and FDA-approved trials of psilocybin and MDMA) could lead to regulatory approval if large-scale trials are positive, but substantial work remains to define safety, standardised therapeutic protocols, and mechanisms. Nutt concludes that while the early data are highly promising, rigorous larger trials, regulatory reform to ease research supply and access, and further mechanistic and implementation studies are needed before psychedelic-assisted treatments can be widely recommended in clinical practice.